Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faith Davies

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|December 20, 2011
How to manage neutropenia in multiple myelomaAntonio Palumbo, Jon Bladé, Mario Boccadoro, et al.
Leukemia|October 16, 2019
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trialCharlotte Pawlyn, David Cairns, Martin Kaiser, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 29, 2019
Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomesMeera Mohan, Sandra Susanibar-Adaniya, Amy Buros, et al.
Blood|July 2, 2002
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myelomaChristian Brander, Noopur Raje, Paula G O'Connor, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
Hematology (Amsterdam, Netherlands)|July 16, 2011
Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysisParameswaran Anoop, Bronwen E Shaw, Unell Riley, et al.
British Journal of Haematology|April 21, 2015
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trialSteve Schey, Sarah R Brown, Avie-Lee Tillotson, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Clinical Lymphoma, Myeloma & Leukemia|December 20, 2011
How to manage neutropenia in multiple myelomaAntonio Palumbo, Jon Bladé, Mario Boccadoro, et al.
Leukemia|October 16, 2019
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trialCharlotte Pawlyn, David Cairns, Martin Kaiser, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 29, 2019
Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomesMeera Mohan, Sandra Susanibar-Adaniya, Amy Buros, et al.
Blood|July 2, 2002
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myelomaChristian Brander, Noopur Raje, Paula G O'Connor, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
Hematology (Amsterdam, Netherlands)|July 16, 2011
Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysisParameswaran Anoop, Bronwen E Shaw, Unell Riley, et al.
British Journal of Haematology|April 21, 2015
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trialSteve Schey, Sarah R Brown, Avie-Lee Tillotson, et al.
Pageof 6